Friday

29th Jul 2016

MEPs back law favouring child medicines

  • 50 per cent of drugs prescribed to children are not tested on children (Photo: www.freeimages.co.uk)

The European Parliament on Wednesday (7 September) voted in favour of a new regulation on medicine, obliging pharmaceutical companies producing a drug for adults in the EU to test whether it can also be used for children.

Named the "Regulation on Medicinal Products for Paediatric Use" the law is aimed at stemming criticism that drugs are generally only tested on adults.

Dear EUobserver reader

Subscribe now for unrestricted access to EUobserver.

Sign up for 30 days' free trial, no obligation. Full subscription only 15 € / month or 150 € / year.

  1. Unlimited access on desktop and mobile
  2. All premium articles, analysis, commentary and investigations
  3. EUobserver archives

EUobserver is the only independent news media covering EU affairs in Brussels and all 28 member states.

♡ We value your support.

If you already have an account click here to login.

"For far too long Europe's children have been waiting, and parents' and patients' organisations have been calling, for special paediatric medicines. Let's not disappoint them," centre-right French MEP Francoise Grossetête wrote in a report ahead of Wednesday's vote.

As medicine is generally only tested on adults, doctors can often only estimate the dose of medicine that should be given to children.

There is also a lack of knowledge about the possible side-effects from the medicine.

Fifty per cent of drugs prescribed to children are not tested on children.

One obstacle for enhanced testing on children has been incentives to pharmaceutical companies to invest more in testing.

Medicine for children's use makes up for a minor part of the medicine market, and pharmaceutical companies have shown little interest in investing in additional tests.

In order to boost research incentives, the newly adopted law says that companies should have an extra six months of protection under existing patents.

Brian Ager, Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA) said he was pleased with the outcome of Wednesday's vote:

"This week's Strasbourg plenary vote is a key opportunity for Europe's children and for Europe's pharmaceutical science base", he said in a press.

But manufacturers of generic low-cost alternatives to patented medicines have protested saying high-cost companies will make too much of a profit on prolonged patents.

The regulation now has to be approved by member states before it can go into force.

EU free movement must be curbed, UK says

British leader Theresa May has said free movement of EU workers to Britain cannot continue as in the past, while visiting Slovakia and Poland on Thursday.

Stakeholders' Highlights

  1. Dialogue Platform
  2. GoogleHelping Emergency Services Find You When You Need It Most
  3. Counter BalanceWhat's New in the Investment Plan for Europe: Business as Usual or True Innovation ?
  4. Belgrade Security ForumMigration, Security and Solidarity within Global Disorder: Academic Event 2016
  5. GoogleHow Google Fights Piracy: Creating Value While Fighting Piracy
  6. EJC"My Visit to Israel" - Opinion by MEP Lopez Aguilar, Chair of the EP Working Group on Antisemitism
  7. World VisionChildren Migrating, Out of School and at Work as Hunger Deepens in Southern Africa
  8. European Healthy Lifestyle AllianceStand-Up (and Exercise) to Prevent Chronic Diseases
  9. Centre Maurits CoppietersLaunches a Real-time News Hub Specialised in EU Stakeholders
  10. GoogleEU-US Privacy Shield: Restoring Faith in Data Flows and Transatlantic Relations
  11. World VisionWorld Leaders & Youth Advocates Launch Partnership to End Violence Vs. Children
  12. Counter BalanceReport: Institutionalised Corruption in Romania's Third Largest Company